An Introduction to Digestive Disorders
Inflammatory bowel disease is a term used to describe chronic, relapsing inflammatory disorders of the digestive tract. The major types are ulcerative colitis, which causes inflammation in the colon, and Crohn’s disease, which may affect any part of the digestive tract, from mouth to anus. Symptoms include abdominal pain, blood in the stool, irregular bowel habits, weight loss and fatigue. Established treatment options are surgery, aminosalicylates, corticosteroids, immunomodulators and anti-TNFα inhibitors; however, many patients will fail to respond or become refractory to these therapies. Emerging therapies include anti-integrin therapy, JAK1 inhibitors, sphingosine-1-phosphate receptor modulators, stem-cell transplant and faecal microbiota transplant.
Our supporting partners do not constitute an endorsement of the content on this page.
Digestive Disorders Content
Stefan Schreiber, ECCO’23: Corticosteroid-free remission with etrasimod in ulcerative colitis – analysis of the ELEVATE UC 52 study
The ELEVATE UC 52 study (NCT03945188) investigated the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis, a recent analysis of the study was presented at ECCO’23 looking at corticosteroid (CS)-free remission as a clinical endpoint. In this touchIMMUNOLOGY interview, we spoke with Dr. Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, […]
Stefan Schreiber, ECCO’23: Current treatment paradigm for ulcerative colitis and corticosteroid-free remission as a treatment goal
The current treatment paradigm for ulcerative colitis (UC) includes amino salicylic acid as a first line treatment followed by corticosteroids, targeted treatment and rectal topical therapy; however, with corticosteroids (CS) impacting long-term health, CS-free remission has become a long-term goal in treatment. Etrasimod is an S1P receptor modulator, recently investigated for the treatment of UC […]
Jean-Frederic Colombel, ECCO 2023: A sub-analysis investigating upadacitinib for rapid symptom relief in Crohn’s disease
The U-EXCEL (NCT03345849) and U-EXCEED (NCT03345836) phase 3 studies investigated the efficacy and safety of upadacitinib, an oral, selective JAK inhibitor in patients with moderate-to-severe Crohn’s disease. touchIMMUNOLOGY were delighted to speak with Dr. Jean-Frederic Colombel (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to discuss his sub-analysis of the data from U-EXCEL […]
Jean-Frederic Colombel, ECCO 2023: LIBERTY-CD: subcutaneous infliximab as Crohn’s disease maintenance therapy
LIBERTY-CD (ClinicalTrials.gov Identifier: NCT03945019) is a phase 3 study investigating the efficacy and safety of subcutaneous infliximab as maintenance therapy in moderately to severely active Crohn’s disease. In this touchIMMUNOLOGY interview we spoke with Dr. Jean-Frederic Colombel (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to discuss the aims, methodology and findings from […]
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Gil Melmed: Crohn’s and Colitis Awareness Week 2022
Crohn’s and colitis awareness week runs from the 1st to the 7th December, this year’s focus is the patient voice and improving quality of life for people affected by Crohn’s and colitis. touchIMMUNOLOGY were delighted to talk with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around the aims of the […]
Lorenzo Bertani, UEG Week 2022: IL-23 serum levels for the prediction of therapeutic response to ustekinumab in Crohn’s disease
Ustekinumab is a human interleukin-12 and -23 antagonist approved for the treatment of Crohn’s disease. touchIMMUNOLOGY were delighted to talk with Dr. Lorenzo Bertani (University of Pisa, Pisa, Italy) to discuss the rationale, methodology and findings from his study investiagting whether baseline IL-23 serum levels could predict therapeutic response to ustekinumab. The abstract entitled ‘BASELINE […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!